AI assistant
Sending…
Design Therapeutics, Inc. — Director's Dealing 2021
Sep 21, 2021
33059_dirs_2021-09-20_c0f246c4-8fb3-41ea-a764-a164061ae449.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Design Therapeutics, Inc. (DSGN)
CIK: 0001807120
Period of Report: 2021-09-13
Reporting Person: Burgess Julie (Chief Accounting Officer)
More from Design Therapeutics, Inc.
Regulatory Filings
2026
May 18
Proxy Solicitation & Information Statement
2026
Apr 23
Annual Report
2026
Apr 23
Regulatory Filings
2026
Apr 1
Major Shareholding Notification
2026
Feb 17
Regulatory Filings
2026
Jan 30
Director's Dealing
2026
Jan 5
Director's Dealing
2026
Jan 5
Director's Dealing
2026
Jan 5
Director's Dealing
2026
Jan 5